文献速递神经肌肉病

高频10-kHz脊髓电刺激治疗痛性糖尿病神经病变的随机临床试验

Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2021-01-01

SENZA-PDN随机临床试验纳入216例难治性痛性糖尿病神经病变患者,比较10-kHz脊髓电刺激联合常规药物治疗与单纯常规药物治疗。结果显示,3个月时联合组79%患者疼痛缓解≥50%,常规组仅5%,6个月时疼痛和神经功能改善持续,安全性可接受。

要点

  • 10-kHz SCS联合常规治疗可显著提高难治性痛性糖尿病神经病变的疼痛缓解率。
  • 联合组6个月时疼痛VAS评分从7.6 cm降至1.7 cm,常规组无显著变化。
  • 联合组神经功能检查改善比例高于常规组,感染需取出装置发生率为2%。

核心结论

  • 10-kHz SCS可安全有效地治疗难治性痛性糖尿病神经病变,显著缓解疼痛并改善生活质量,效果持续6个月。

研究设计与样本

  • 前瞻性、多中心、开放标签随机临床试验,比较10-kHz SCS联合常规药物治疗与单纯常规药物治疗。
  • 2017年8月至2019年8月在美国多个中心招募216例难治性痛性糖尿病神经病变患者,随机分组,6个月随访,6个月时可选交叉。

主要发现

  • 主要终点(3个月时VAS疼痛缓解≥50%且神经功能无恶化)在常规组达到5/94(5%),联合组75/95(79%),差异73.6%(95%CI 64.2-83.0,P<.001)。
  • 6个月时联合组平均疼痛VAS评分从基线7.6 cm(95%CI 7.3-7.9)降至1.7 cm(95%CI 1.3-2.1),常规组从7.0 cm(95%CI 6.7-7.3)降至6.9 cm(95%CI 6.5-7.3)。
  • 6个月时神经功能检查改善在常规组为3/92(3%),联合组为52/84(62%),差异58.6%(95%CI 47.6-69.6,P<.001)。
  • 联合组2例(2%)发生需取出装置的感染。

关键数值与推荐

  • 纳入标准:痛性糖尿病神经病变≥1年,对加巴喷丁类药物和至少一种其他镇痛药无效,下肢疼痛VAS≥5 cm,BMI≤45,HbA1c≤10%,每日吗啡当量≤120 mg。
  • 主要终点:3个月时VAS疼痛缓解≥50%且基线神经功能缺损无恶化。

临床怎么用

  • 对于药物难治性痛性糖尿病神经病变患者,可考虑转诊评估10-kHz SCS治疗。
  • 治疗决策需结合患者合并症、感染风险及装置植入可行性。

局限性

  • 开放标签设计可能引入偏倚。
  • 6个月随访时间较短,长期疗效和安全性未明。
  • 6个月时允许交叉,可能影响后续比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Many patients with diabetic peripheral neuropathy experience chronic pain and inadequate relief despite best available medical treatments. OBJECTIVE: To determine whether 10-kHz spinal cord stimulation (SCS) improves outcomes for patients with refractory painful diabetic neuropathy (PDN). DESIGN, SETTING, AND PARTICIPANTS: The prospective, multicenter, open-label SENZA-PDN randomized clinical trial compared conventional medical management (CMM) with 10-kHz SCS plus CMM. Participants with PDN for 1 year or more refractory to gabapentinoids and at least 1 other analgesic class, lower limb pain intensity of 5 cm or more on a 10-cm visual analogue scale (VAS), body mass index (calculated as weight in kilograms divided by height in meters squared) of 45 or less, hemoglobin A1c (HbA1c) of 10% or less, daily morphine equivalents of 120 mg or less, and medically appropriate for the procedure were recruited from clinic patient populations and digital advertising. Participants were enrolled from multiple sites across the US, including academic centers and community pain clinics, between August 2017 and August 2019 with 6-month follow-up and optional crossover at 6 months. Screening 430 patients resulted in 214 who were excluded or declined participation and 216 who were randomized. At 6-month follow-up, 187 patients were evaluated. INTERVENTIONS: Implanted medical device delivering 10-kHz SCS. MAIN OUTCOMES AND MEASURES: The prespecified primary end point was percentage of participants with 50% pain relief or more on VAS without worsening of baseline neurological deficits at 3 months. Secondary end points were tested hierarchically, as prespecified in the analysis plan. Measures included pain VAS, neurological examination, health-related quality of life (EuroQol Five-Dimension questionnaire), and HbA1c over 6 months. RESULTS: Of 216 randomized patients, 136 (63.0%) were male, and the mean (SD) age was 60.8 (10.7) years. Additionally, the median (interquartile range) duration of diabetes and peripheral neuropathy were 10.9 (6.3-16.4) years and 5.6 (3.0-10.1) years, respectively. The primary end point assessed in the intention-to-treat population was met by 5 of 94 patients in the CMM group (5%) and 75 of 95 patients in the 10-kHz SCS plus CMM group (79%; difference, 73.6%; 95% CI, 64.2-83.0; P < .001). Infections requiring device explant occurred in 2 patients in the 10-kHz SCS plus CMM group (2%). For the CMM group, the mean pain VAS score was 7.0 cm (95% CI, 6.7-7.3) at baseline and 6.9 cm (95% CI, 6.5-7.3) at 6 months. For the 10-kHz SCS plus CMM group, the mean pain VAS score was 7.6 cm (95% CI, 7.3-7.9) at baseline and 1.7 cm (95% CI, 1.3-2.1) at 6 months. Investigators observed neurological examination improvements for 3 of 92 patients in the CMM group (3%) and 52 of 84 in the 10-kHz SCS plus CMM group (62%) at 6 months (difference, 58.6%; 95% CI, 47.6-69.6; P < .001). CONCLUSIONS AND RELEVANCE: Substantial pain relief and improved health-related quality of life sustained over 6 months demonstrates 10-kHz SCS can safely and effectively treat patients with refractory PDN. TRIAL REGISTRATION: ClincalTrials.gov Identifier: NCT03228420.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 33818600. doi:10.1001/jamaneurol.2021.0538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。